On Friday, Shares of Ampio Pharmaceuticals Inc (NYSEMKT:AMPE), lost -5.81% to $2.27.
Ampio Pharmaceuticals, declared positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).
The aim of the study was to assess the safety and efficacy of oral Optina, identify the patients who respond and the ideal dose.
- Orally administered Optina was extremely safe with no drug related serious adverse events. There were no differences in side effect rates between placebo and the Optina arms.
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depletion of the accessible phosphate needed for the inflammation process; and decreasing vascular permeability
Shares of Tyson Foods, Inc.(NYSE:TSN), declined -1.24% to $42.95, during its last trading session.
Tyson Foods, told investors at the BMO Farm to Market conference that the company is plannedally diversified because it combines branded consumer products, commodity protein production and prepared foods and value-added chicken for the food service industry.
“Tyson Foods is in a preferred position and a unique position,” Donnie Smith, president and chief executive officer, said. “We have the protein consumers want to eat, and we have the #1 brands in those categories. We have the research and development expertise and consumer insights behind those #1 brands to keep driving innovation. We have the raw materials to make those innovative products, and we’re a food company that’s growing.”
“Our aim is to deliver top-tier performance in the food industry,” said Andy Callahan, president of retail packaged brands. “We have an advantaged portfolio with a preferred position to grow ahead of the competition. Our brand building model has a proven track record of growth, and our new product pipeline is robust.”
Tyson Foods, Inc., together with its auxiliaries, produces, distributes, and markets chicken, beef, pork, prepared foods, and related allied products worldwide. The company breeds and raises chickens; and processes live chickens into fresh, frozen, and value-added chicken products.
At the end of Friday’s trade, Shares of StemCells Inc (NASDAQ:STEM), gained 10.70% to $ 0.6787.
StemCells, Inc. (STEM), declared that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell (HuCNS-SC) intramedullary transplantation in thoracic spinal cord injury. The summary will be presented recently at 10:15 a.m. EDT at the 4th Joint International Spinal Cord Society (ISCoS) and American Spinal Injury Association (ASIA) meeting being held in Montreal, Canada. The abstract was selected as one of the top six platform submissions for the conference.
The international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of StemCells, Inc.’s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord and were in the early chronic stage of recovery. The severity of spinal cord trauma is classified by the ASIA Impairment Scale (AIS) according to the degree of sensory and motor loss. Patients classified as AIS A, the most severe injury, have lost both sensory and motor function below the level of injury. AIS B patients are considered less severely injured because, although they also have no motor function below the level of injury, some limited sensory function is maintained. The protocol was specifically designed to test safety and preliminary efficacy across this spectrum of injury severity, and ultimately the trial transplanted seven AIS A and five AIS B patients.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development.
Finally, Marsh & McLennan Companies, Inc. (NYSE:MMC), ended its last trade with -0.17% lost, and closed at $59.00.
Marsh & McLennan Companies, held its annual meeting of shareholders at which the Company declared that its Board of Directors voted to enhance both the Company’s quarterly cash dividend and share repurchase program.
The Board of Directors raised the quarterly cash dividend by 11% from $.28 to $.31 per share on outstanding common stock. The dividend is payable on August 14, 2015 to shareholders of record on July 10, 2015.
The Board also authorized an enhance in the Company’s share repurchase program, allowing administration to buy back up to $2 billion of the Company’s common stock going forward, which supersedes any preceding authorization.
Marsh & McLennan Companies, Inc., a professional services firm, provides advice and solutions primarily in the areas of risk, strategy, and people worldwide. It operates in two segments, Risk and Insurance Services; and Consulting.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
